<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438929</url>
  </required_header>
  <id_info>
    <org_study_id>DO607227A</org_study_id>
    <nct_id>NCT03438929</nct_id>
  </id_info>
  <brief_title>Evaluation of Diolaze XL Blended Mode for Hair Removal</brief_title>
  <official_title>Clinical Evaluation of Diolaze XL Blended Mode for Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InMode MD Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InMode MD Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate safety and efficiency of Diolase XL&#xD;
      blended modes for hair removal. The handpieces tested were a blend of 755nm/810nm and&#xD;
      810nm/1064nm. At least 30 female subjects seeking hair removal treatment will be enrolled.&#xD;
      Treatment sites will be o groins and axillae. Study design included 3 treatment sessions 4&#xD;
      weeks apart and follow-up after 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Actual">February 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair reduction</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Hair reduction of at least 30% at follow-up visit comparing to baseline count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recording of frequency, severity and causality of adverse events (Safety)</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Observation, assessment and recording of reactions by the investigator.</description>
  </primary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Hair Removal</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diode laser</intervention_name>
    <description>Diolaze XL blended modes diode laser</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult females between the ages of 18-65, seeking hair removal treatments.&#xD;
&#xD;
          -  Subjects skin type II-V.&#xD;
&#xD;
          -  Subjects should understand the information provided about the investigative nature of&#xD;
             the treatment, possible benefits and side effects, and sign the Informed Consent Form,&#xD;
             (including the permission to use photography).&#xD;
&#xD;
          -  Subjects should be willing to comply with the study procedure and schedule, including&#xD;
             the follow up visit, to refrain from using any other aesthetic treatment methods in&#xD;
             the treatment areas such as other hair removal methods (wax, IPL, laser), Botox or&#xD;
             other technologies for hyperhidrosis or rejuvenation for the last 6 months and during&#xD;
             the entire study period and to remain unshaven for a minimum of 3 days before their&#xD;
             visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of skin cancer, or current condition of any other type of cancer,&#xD;
             or pre-malignant moles.&#xD;
&#xD;
          -  Pregnancy and nursing.&#xD;
&#xD;
          -  Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use&#xD;
             of immunosuppressive medications.&#xD;
&#xD;
          -  Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex&#xD;
             in the treatment area, may be treated only following a prophylactic regimen.&#xD;
&#xD;
          -  Poorly controlled endocrine disorders, such as diabetes, thyroid dysfunction,&#xD;
             polycystic ovary and hormonal virilization.&#xD;
&#xD;
          -  Any active condition in the treatment area, such as sores, psoriasis, eczema, and&#xD;
             rash.&#xD;
&#xD;
          -  History of skin disorders, keloids, abnormal wound healing, as well as very dry and&#xD;
             fragile skin.&#xD;
&#xD;
          -  Severe concurrent conditions, such as cardiac disorders, sensory disturbances.&#xD;
&#xD;
          -  Use of Isotretinoin (AccutaneÂ®) within 6 months prior to treatment.&#xD;
&#xD;
          -  Known skin photosensitivity or using drugs increasing skin photosensitivity.&#xD;
&#xD;
          -  Diseases that may be stimulated by light, such as epilepsy, lupus and urticaria.&#xD;
&#xD;
          -  Six months delay is recommended if other recent treatments like light, laser or RF&#xD;
             were performed on the same area.&#xD;
&#xD;
          -  Treating over tattoo and permanent make-up.&#xD;
&#xD;
          -  Fresh tan from sun, sunbeds or chemicals or planned excessive sun exposure.&#xD;
&#xD;
          -  Vitiligo.&#xD;
&#xD;
          -  As per the practitioner's discretion, refrain from treating any condition which might&#xD;
             make it unsafe for the patient.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hela Goren, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>InMode MD Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InMode MD Ltd.</name>
      <address>
        <city>Yokneam</city>
        <zip>20692</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

